Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew Craig Kapusta CPA | CEO & Executive Director | 20.29M | -- | 1972 |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 11.48M | -- | 1973 |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | 14.6M | -- | 1969 |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 12.67M | -- | 1962 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | -- | -- | -- |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer | -- | -- | -- |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | -- | -- | -- |
| Ms. Erin Boyer | Chief People & Culture Officer | -- | -- | -- |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | -- | -- | 1965 |
| Eileen Sawyer | Vice President of Global Medical Affairs | -- | -- | -- |
uniQure N.V.
- Full Time Employees:
- 209
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Corporate Governance
Upcoming Events
February 27, 2025 at 12:05 PM UTC
uniQure N.V. Earnings Date
Recent Events
Recent Events Information Not Available